Have a feature idea you'd love to see implemented? Let us know!

SVRA Savara Inc

Price (delayed)

$3.6

Market cap

$592.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$595.18M

Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management ...

Highlights
Savara's equity has decreased by 17% from the previous quarter but it has increased by 16% YoY
SVRA's net income has plunged by 76% YoY and by 17% from the previous quarter
The company's EPS has shrunk by 50% YoY and by 14% QoQ

Key stats

What are the main financial stats of SVRA
Market
Shares outstanding
164.6M
Market cap
$592.56M
Enterprise value
$595.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.89
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$72.32M
EBITDA
-$72.06M
Free cash flow
-$72M
Per share
EPS
-$0.42
Free cash flow per share
-$0.39
Book value per share
$0.74
Revenue per share
$0
TBVPS
$0.76
Balance sheet
Total assets
$139.67M
Total liabilities
$37.94M
Debt
$26.48M
Equity
$101.73M
Working capital
$116.41M
Liquidity
Debt to equity
0.26
Current ratio
11.31
Quick ratio
10.77
Net debt/EBITDA
-0.04
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-45.8%
Return on equity
-59%
Return on invested capital
-46.1%
Return on capital employed
-56.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SVRA stock price

How has the Savara stock price performed over time
Intraday
-0.96%
1 week
3.45%
1 month
-9.77%
1 year
-1.37%
YTD
-23.4%
QTD
-15.09%

Financial performance

How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.34M
Net income
-$75.29M
Gross margin
N/A
Net margin
N/A
Savara's operating income has plunged by 78% YoY and by 16% from the previous quarter
SVRA's net income has plunged by 76% YoY and by 17% from the previous quarter

Growth

What is Savara's growth rate over time

Valuation

What is Savara stock price valuation
P/E
N/A
P/B
4.89
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has shrunk by 50% YoY and by 14% QoQ
The stock's price to book (P/B) is 122% more than its 5-year quarterly average of 2.2
Savara's equity has decreased by 17% from the previous quarter but it has increased by 16% YoY

Efficiency

How efficient is Savara business performance
SVRA's return on assets is down by 44% year-on-year and by 13% since the previous quarter
SVRA's ROE is down by 42% YoY and by 13% from the previous quarter
Savara's ROIC has decreased by 15% from the previous quarter and by 7% YoY

Dividends

What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SVRA.

Financial health

How did Savara financials performed over time
SVRA's quick ratio is down by 40% YoY and by 26% from the previous quarter
SVRA's current ratio is down by 38% year-on-year and by 24% since the previous quarter
The debt is 74% smaller than the equity
The debt to equity has grown by 18% from the previous quarter but it has contracted by 13% YoY
Savara's equity has decreased by 17% from the previous quarter but it has increased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.